Alnylam Pharmaceuticals (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The provided filing excerpts contain only the SEC cover-page boilerplate and do not disclose segment revenue, product names, commercial stage details, customer data, geographic mix, or competitive positioning. Because the filing text supplied does not support specific factual claims about Alnylam's business model, revenue streams, products, markets, or competitors, those details are omitted per source-grounding rules. A complete business description requires access to the full 10-K body sections, including Item 1 (Business), Item 7 (MD&A), and the financial statements from the annual report filed 2026-02-12 under accession 000162828026007497.

Source: SEC 10-K, filed 2026-02-12

Industry: Pharmaceutical Preparations Peers: Biogen Inc Biohaven Pharmaceutical Holding Co Ltd. BioMarin Pharmaceutical Inc Incyte Corp Moderna Inc Neurocrine Biosciences Inc Regeneron Pharmaceuticals Inc Seagen Inc. Vertex Pharmaceuticals Inc